ArticleInternational journal of biological sciences2021
HES1 promotes breast cancer stem cells by elevating Slug in triple-negative breast cancer.
Article in International journal of biological sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 29 citations in OpenAlex.
- Causal relationship and pathogenic mechanism analysis of breast cancer and coronary heart disease based on mendelian randomization and transcriptome data analysis.Immunogenetics · 2026Article
- Combining Spatial Multi-Omics Data to Decipher Spatial Domains and Elucidate Cell Heterogeneity Based on Self-Supervised Graph Learning.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- HES1 in cancer: a key player in tumorigenesis and its prognostic significance.Molecular genetics and genomics : MGG · 2025Review
- PTEN and HES1 Gene Expression Alteration in Breast Cancer: Any Association with Tumor Histomorphological Features or Invasive Behavior?Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Dimeric CCK2R radiotheranostic tracers synergize with mTOR inhibition for enhanced tumor therapy.Theranostics · 2025Article
- Hes1 in malignant tumors: from molecular mechanism to therapeutic potential.Frontiers in immunology · 2025Review
- Disrupting Notch signaling related HES1 in myeloid cells reinvigorates antitumor T cell responses.Experimental hematology & oncology · 2024Article
- HES1 revitalizes the functionality of aged adipose-derived stem cells by inhibiting the transcription of STAT1.Stem cell research & therapy · 2024Article
- Altered Phenotypes of Breast Epithelial × Breast Cancer Hybrids after ZEB1 Knock-Out.International journal of molecular sciences · 2023Article
- HES1 promotes aerobic glycolysis and cancer progression of colorectal cancer via IGF2BP2-mediated GLUT1 m6A modification.Cell death discovery · 2023Article
- Article
- A novel ferroptosis‑related gene signature for overall survival prediction and immune infiltration in patients with breast cancer.International journal of oncology · 2022Article
- Review
- HSP90 N-terminal inhibitors target oncoprotein MORC2 for autophagic degradation and suppress MORC2-driven breast cancer progression.Clinical and translational medicine · 2022Article
- Effects of Pubertal Exposure to Butyl Benzyl Phthalate, Perfluorooctanoic Acid, and Zeranol on Mammary Gland Development and Tumorigenesis in Rats.International journal of molecular sciences · 2022Article
- A novel autophagy-related genes prognostic risk model and validation of autophagy-related oncogene VPS35 in breast cancer.Cancer cell international · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer. TNBC is enriched with breast cancer stem cells (BCSCs), which are responsible for cancer initiation, cancer progression and worse prognosis. Our previous study found that HES1 was overexpressed and promoted invasion in TNBC. However, the role of HES1 in modulating BCSC stemness of TNBC remains unclear. Here, we found that HES1 upregulates Slug both in transcriptional level and in protein level. HES1 also has a positive correlation with Slug expression in 150 TNBC patient samples. TNBC patients with high HES1 and Slug levels show worse prognosis in both progression-free survival and overall survival analyses. Survival analyses indicate that the effects of HES1 on survival prognosis may depend on Slug. Furthermore, we reveal that HES1 is a novel transcriptional activator for Slug through acting directly on its promoter. Meanwhile, HES1 knockdown reduces BCSC self-renewal, BCSC population, and cancer cell proliferation in TNBC, whereas overexpression of Slug restores the oncogenic function of HES1, both
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.